Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 in Erythropoiesis Stimulating Agent-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

NCT02780141 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02780141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02780141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 in Erythropoiesis Stimulating Agent-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
June 2, 2016
Completion date
December 12, 2017
Enrollment
75 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

esa-naive hemodialysis chronic kidney disease patients with anemia